Trial Profile

A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lucerastat (Primary)
Indications Fabry's disease; Neuropathic pain
Focus Registrational; Therapeutic Use
Acronyms MODIFY
Sponsors Idorsia Pharmaceuticals

Most Recent Events

30 Jan 2026 According to an Idorsia media release, the company is finalizing the development plan for the optimal regulatory pathway to approval
30 Jan 2026 According to an Idorsia media release, data from the trial were presented in Nature Communications.
30 Jan 2026 According to an Idorsia media release, data from the trial will be presented at the 22nd Annual WORLDSymposium, taking place from February 2-6, 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com